血液培養検査市場- 世界の産業規模、シェア、動向、機会、予測、製品別、用途別、技術別、地域別、競合別、2019年～2029年

血液培養検査の世界市場は、2023年に58億7,000万米ドルと評価され、2029年までのCAGRは10.01%で、予測期間中に力強い成長が予測されています。

この市場には、患者の血流中の細菌、真菌、ウイルスなどの病原体の存在を検出するために設計された幅広い診断製品およびサービスが含まれます。血液培養検査の需要は、いくつかの要因によって世界中で着実に増加しています。

感染症の増加と敗血症の有病率の増加は、正確で迅速な診断ツールの重要性を強調しています。血液培養検査は、ヘルスケア専門家に的を絞った抗生物質療法に不可欠な情報を提供し、患者の転帰改善に貢献します。さらに、血流感染症の早期発見の必要性に対する認識が高まっていることも、市場の成長に拍車をかけています。

技術の進歩もまた、世界の血液培養検査市場の拡大に重要な役割を果たしています。自動血液培養システム、高度な分子診断技術、改良された血液培養培地などの技術革新により、これらの検査の感度と特異度が向上し、偽陽性と偽陰性が減少しました。その結果、患者ケアとヘルスケアシステムの効率が向上しました。

市場は研究開発への投資が増加し、その結果、新しい診断技術が開発され、使いやすく費用対効果の高い血液培養キットが導入されました。その結果、先進国、発展途上国を問わず、医療施設での血液培養検査の導入が進み、より広範な消費者が血液培養検査を利用するようになっています。

主な市場促進要因

感染症および敗血症の有病率の上昇

技術の進歩

意識の高まりと早期発見の重視

主な市場課題

高いコストと経済的障壁

汚染リスク

主な市場動向

抗生物質耐性病原体の増加

研究開発投資

セグメント別洞察

製品別洞察

用途別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 血液培養検査の世界市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別（消耗品、器具）
  • 用途別（細菌感染症、真菌感染症、マイコバクテリア感染症）
  • 技術別（従来型、自動化）
  • 企業別（2023年）
  • 地域別
• 市場マップ

第6章 北米の血液培養検査市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別
  • 用途別
  • 技術別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の血液培養検査市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別
  • 用途別
  • 技術別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋の血液培養検査市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別
  • 用途別
  • 技術別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の血液培養検査市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別
  • 用途別
  • 技術別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの血液培養検査市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品別
  • 用途別
  • 技術別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併買収（もしあれば）
• 製品上市（もしあれば）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Becton Dickinson Company
• Terumo Corporation
• Bruker Corporation
• bioMerieux
• T2 Biosystems Inc.
• Luminex Corporation
• Abbott Laboratories Inc.
• Siemens Healthineers AG
• Danaher Corporation
• F. Hoffmann-La Roche Ltd

第15章 戦略的提言

第16章 免責事項

Global Blood Culture Tests Market was valued at USD 5.87 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 10.01% through 2029.The Global Blood Culture Test Market has emerged as a critical component of modern healthcare, playing a pivotal role in the diagnosis and management of various infectious diseases. This market encompasses a wide array of diagnostic products and services designed to detect the presence of pathogens such as bacteria, fungi, and viruses in a patient's bloodstream. The demand for blood culture tests has been steadily increasing worldwide, driven by several factors.

The rise in infectious diseases and the increasing prevalence of sepsis have accentuated the importance of accurate and rapid diagnostic tools. Blood culture tests provide healthcare professionals with essential information for targeted antibiotic therapy, thus contributing to better patient outcomes. Additionally, the growing awareness of the need for early detection of bloodstream infections has fueled the market's growth.

Technological advancements have also played a significant role in the expansion of the global blood culture test market. Innovations such as automated blood culture systems, advanced molecular diagnostic techniques, and improved blood culture media have enhanced the sensitivity and specificity of these tests, reducing false positives and false negatives. This, in turn, has improved patient care and the efficiency of healthcare systems.

The market has witnessed increased investment in research and development, resulting in the development of novel diagnostic technologies and the introduction of user-friendly, cost-effective blood culture kits. As a result, healthcare facilities in both developed and developing regions are increasingly adopting blood culture tests, leading to broader consumer.

Key Market Drivers

Rising Prevalence of Infectious Diseases and Sepsis

The rising prevalence of infectious diseases and sepsis is a significant driver behind the robust growth of the global blood culture test market. Infectious diseases, including sepsis, have witnessed a steady increase in their incidence worldwide, making early and accurate diagnosis more critical than ever. Sepsis, in particular, is a life-threatening condition that can lead to organ failure and death if not promptly identified and treated. Blood culture tests have emerged as a cornerstone in the battle against sepsis, enabling healthcare professionals to swiftly detect the causative pathogens and administer targeted antibiotic therapy. With the World Health Organization reporting millions of sepsis cases each year, the importance of precise diagnostics cannot be overstated.

In addition to sepsis, the global burden of other infectious diseases, such as bacterial and fungal infections, has also been on the rise. This surge in infectious disease prevalence is attributed to various factors, including antimicrobial resistance, international travel, and changing healthcare dynamics. As pathogens become more resilient to conventional treatments, accurate identification and tailored therapies become indispensable. Blood culture tests fill this crucial role by providing a definitive diagnosis and guidance on the most effective antibiotics to combat the infection, thereby improving patient outcomes.

The increasing awareness of the urgency in diagnosing infectious diseases and sepsis has led to a higher demand for blood culture tests. Healthcare professionals and the general public have recognized the pivotal role that these tests play in preventing disease progression, minimizing complications, and reducing mortality rates. The need for timely and reliable diagnostics has driven healthcare institutions to prioritize the integration of blood culture tests into their standard protocols, further boosting the market.

Technological Advancements

Technological advancements are a driving force behind the rapid growth of the global blood culture test market. These innovations have revolutionized the field of diagnostic microbiology, making blood culture tests more efficient, accurate, and accessible. The adoption of advanced technologies has significantly enhanced the sensitivity and specificity of these tests, resulting in quicker and more precise pathogen identification.

One of the most prominent technological advancements is the development of automated blood culture systems. These systems have streamlined the testing process, reducing the time required for obtaining results and minimizing the risk of contamination. Automation allows for continuous monitoring of blood cultures, enabling healthcare professionals to detect microbial growth as soon as it occurs. This real-time data is invaluable for prompt intervention and tailored antibiotic therapy, particularly in critical cases like sepsis.

Molecular diagnostic techniques have also played a pivotal role in advancing blood culture tests. Techniques like polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) have transformed pathogen identification. PCR, for instance, allows for the amplification and detection of specific DNA or RNA sequences, offering rapid and highly accurate results. MALDI-TOF MS enables the identification of microorganisms based on their protein profiles, enhancing the specificity of blood culture testing.

Improvements in blood culture media have further bolstered the performance of these tests. The development of specialized culture media that support the growth of a wide range of pathogens has expanded the diagnostic capabilities of blood culture tests. This has translated to higher sensitivity in detecting various infectious agents, including bacteria, fungi, and even antibiotic-resistant strains.

These technological advancements have not only enhanced diagnostic accuracy but have also made the tests more user-friendly for healthcare professionals. Simpler and more efficient workflows have reduced the burden on laboratory staff, resulting in quicker turnaround times for test results. The combination of automation, molecular techniques, and optimized culture media has improved the overall efficiency of blood culture tests, providing critical information for early intervention and precise antibiotic therapy.

Growing Awareness and Emphasis on Early Detection

The global blood culture test market is experiencing a significant boost due to the growing awareness and emphasis on early detection of infectious diseases and sepsis. Healthcare professionals and the general public are increasingly recognizing the critical role that timely and accurate diagnosis plays in managing these conditions. This heightened awareness is driving the demand for blood culture tests and is reshaping the landscape of modern healthcare.

Early detection is vital in the management of infectious diseases. Blood culture tests have emerged as a frontline diagnostic tool in this regard, allowing healthcare providers to swiftly and precisely identify the causative pathogens within a patient's bloodstream. With timely diagnosis, appropriate treatment strategies can be initiated, reducing the risk of disease progression, complications, and, in the case of sepsis, mortality.

Sepsis, in particular, has garnered significant attention in recent years due to its high mortality rates and the need for rapid diagnosis. The ability of blood culture tests to detect the specific pathogens responsible for sepsis allows for targeted antibiotic therapy, optimizing patient care and outcomes. The World Health Organization and numerous healthcare organizations have actively promoted the early detection and management of sepsis, creating a global emphasis on improving diagnostic capabilities.

Patients themselves are also increasingly aware of the importance of early detection, leading them to seek prompt medical attention for symptoms of infection. This awareness has created a demand for reliable diagnostic tools like blood culture tests that can provide a definitive diagnosis, guide treatment decisions, and ultimately improve patient well-being.

Healthcare providers have integrated early detection into their standard protocols and best practices. The availability of blood culture tests in healthcare facilities is becoming more widespread, ensuring that patients have access to these vital diagnostic tools in a timely manner. This strategic focus on early detection has driven healthcare institutions to invest in the necessary equipment and staff training, further bolstering the market.

Key Market Challenges

High Costs and Financial Barriers

One of the primary financial barriers hindering the global blood culture test market is the high capital investment required for acquiring and maintaining the necessary equipment. Automated blood culture systems, which offer streamlined and efficient testing processes, often come with a hefty price tag. These automated systems not only require a considerable initial investment but also ongoing maintenance costs. Smaller healthcare facilities, especially in resource-constrained regions, may find it challenging to allocate the necessary financial resources for such equipment, limiting their capacity to provide advanced blood culture testing services.

Beyond equipment costs, there is a need for skilled personnel to operate and interpret the results of blood culture tests accurately. The training and expertise required to perform these tests effectively add another layer of cost. This cost extends not only to the hiring and retention of laboratory professionals but also to the continuous training and education necessary to keep them updated with the latest advancements in blood culture testing.

Routine maintenance of equipment and quality assurance measures are essential to ensure the accuracy and reliability of blood culture tests. These ongoing costs, while critical for ensuring the quality of diagnostic services, can become a financial burden for healthcare facilities. Inadequate budget allocation for maintenance can compromise the performance of the equipment and the accuracy of test results.

Contamination Risk

Contamination during the blood collection and handling process can lead to false positive results. When the culture medium intended to support the growth of microorganisms is inadvertently contaminated with external bacteria or other contaminants, it can give the appearance of an infection that is not actually present. False positive results can lead to unnecessary treatments, including the administration of antibiotics, which can have adverse consequences for patients.

False positive results due to contamination can lead to extended hospital stays for patients as healthcare providers attempt to address the perceived infection. Prolonged hospitalization can increase healthcare costs, place an additional burden on the patient, and may expose them to potential hospital-acquired infections.

The presence of contamination can complicate clinical decision-making. Healthcare providers may be unsure whether a positive blood culture result is due to a true infection or contamination, leading to uncertainty in treatment decisions. This can result in delayed or inappropriate care, affecting patient outcomes.

Contaminated blood cultures require additional resources for investigation, validation, and retesting. Identifying the source of contamination and confirming the accuracy of results can be time-consuming and costly. The financial resources required to address false positive results due to contamination can strain healthcare budgets.

Contamination risk also places an increased workload on clinical laboratories. Laboratory personnel must carefully manage and investigate potential contamination events, diverting their attention from other critical tasks. This can slow down the overall testing process, affecting turnaround times for all patients.

Key Market Trends

Rising Incidence of Antibiotic-Resistant Pathogens

The rising incidence of antibiotic-resistant pathogens has emerged as a significant driver in boosting the global blood culture test market. Antibiotic resistance, a growing global health concern, has made it increasingly challenging to effectively treat infections. As pathogens develop resistance to commonly used antibiotics, identifying the specific causative agents of infections becomes crucial for tailoring precise and targeted treatments. Blood culture tests play a pivotal role in this scenario by providing rapid and accurate pathogen identification, allowing healthcare professionals to select the most appropriate antibiotics.

The threat of antibiotic-resistant pathogens has grown so pervasive that it is no longer confined to specific regions or demographics. Resistant strains of bacteria, fungi, and other pathogens have become a global issue, affecting patients of all ages and backgrounds. The ability of blood culture tests to detect and identify these resistant strains is of paramount importance, as it ensures that patients receive effective treatment from the outset, reducing the risk of complications and the spread of resistance.

The rise of multi-drug-resistant infections has increased the urgency of early diagnosis and intervention. Healthcare institutions and professionals worldwide have recognized the limitations of broad-spectrum antibiotics and the necessity of targeted therapies. Blood culture tests provide critical information to guide treatment decisions, preventing the inappropriate use of antibiotics, which contributes to the development of resistance.

Research and Development Investments

Research and development (RD) investments have emerged as a significant driving force behind the expansion of the global blood culture test market. These investments are instrumental in fostering innovation, advancing diagnostic technologies, and enhancing the overall performance of blood culture tests. As healthcare professionals and institutions recognize the pivotal role that accurate and rapid diagnosis plays in managing infectious diseases and sepsis, RD initiatives have gained momentum, fueling the market's growth.

In recent years, RD efforts have led to the development of cutting-edge diagnostic technologies that have transformed the landscape of blood culture testing. Automated blood culture systems, for example, have revolutionized the testing process, reducing the time required for obtaining results and minimizing the chances of contamination. These systems provide continuous monitoring, enabling healthcare professionals to detect microbial growth in real time. Additionally, advanced molecular diagnostic techniques, such as polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), have significantly improved pathogen identification, making it faster and more accurate.

The development of specialized blood culture media has also been a product of RD investments. These media are designed to support the growth of a wide range of pathogens, including bacteria, fungi, and antibiotic-resistant strains. This expansion in the capabilities of blood culture tests has resulted in higher sensitivity and specificity, reducing false positives and false negatives.

RD investments have led to the creation of user-friendly and cost-effective blood culture kits, making these tests more accessible to a broader range of healthcare facilities. These innovations have not only improved the performance and efficiency of blood culture tests but have also reduced the complexity and cost of implementing these diagnostics, leading to their broader adoption.

Segmental Insights

Product Insights

Based on the product,consumables emerged as the dominant segment in the global market for global blood culture tests market in 2023.Consumables encompass various components essential for conducting blood culture tests, including culture media, blood collection bottles, and ancillary supplies. The dominance of consumables in the market is primarily due to the continuous demand for these products across healthcare facilities worldwide. The dominance of consumables is due to the increasing prevalence of infectious diseases globally. Infectious diseases, caused by bacteria, fungi, viruses, or parasites, pose significant public health challenges and require prompt and accurate diagnosis for effective management. Blood culture tests are essential diagnostic tools used to identify the presence of microorganisms in the bloodstream, aiding in the diagnosis and treatment of infectious diseases. As the incidence of infectious diseases continues to rise, there is a corresponding increase in the demand for consumables used in blood culture testing procedures.

Application Insights

Based on the application, bacterial infections emerged as the dominant segment in the global market for global blood culture tests market in 2023.Bacterial infections are among the most common infectious diseases worldwide. They encompass a wide range of conditions, including urinary tract infections, respiratory infections, bloodstream infections, and more. Bacterial infections affect individuals of all ages and backgrounds, making them a global health concern. This high prevalence of bacterial infections necessitates the frequent use of blood culture tests for accurate diagnosis. Bacterial infections can range from mild and self-limiting to severe and life-threatening. Timely and accurate diagnosis is critical, particularly in cases of sepsis, a severe and potentially fatal condition resulting from bacterial infections. Blood culture tests are instrumental in identifying the specific bacterial pathogens causing bloodstream infections, which is crucial for rapid intervention and targeted antibiotic therapy.

Regional Insights

North America emerged as the dominant region in the global blood culture tests market in 2023, holding the largest marketshare.North America has experienced an increasing prevalence of infectious diseases and sepsis, driven by factors such as a growing aging population, antibiotic resistance, and various healthcare-associated infections. This rise in infectious diseases has led to a higher demand for blood culture tests as a crucial diagnostic tool. Healthcare providers in North America have placed a significant emphasis on early detection and diagnosis of infectious diseases and sepsis. A timely and accurate diagnosis is essential for initiating appropriate treatment promptly. This emphasis has led to the widespread adoption of blood culture tests in clinical practice.North America is a hub for research and development in the healthcare and diagnostics sectors. The region has seen substantial investments in the development of advanced blood culture systems, molecular diagnostic techniques, and improved culture media. These innovations have enhanced the sensitivity and specificity of blood culture tests, making them more efficient and reliable.

Key Market Players

Becton Dickinson Company

Terumo Corporation

Bruker Corporation

bioMerieux

T2 Biosystems Inc.

Luminex Corporation

Abbott Laboratories Inc.

Siemens Healthineers AG

Danaher Corporation

F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Blood Culture Tests Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Blood Culture Tests Market,By Product:

• Consumables
• Instruments

Global Blood Culture Tests Market,By Application:

• Bacterial Infections
• Fungal Infections
• Mycobacterial Infections

Global Blood Culture Tests Market,By Technique:

• Conventional
• Automated

Global Blood Culture Tests Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Culture Tests Market.

Available Customizations:

Global Blood Culture Tests Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, and Trends

4.Voice of Customer

5.Global Blood Culture Tests Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Product (Consumables, Instruments)
  • 5.2.2.By Application (Bacterial Infections, Fungal Infections, Mycobacterial Infections)
  • 5.2.3.By Technique (Conventional, Automated)
  • 5.2.4.By Company (2023)
  • 5.2.5.By Region
• 5.3.Market Map

6.North America Blood Culture Tests Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Product
  • 6.2.2.By Application
  • 6.2.3.By Technique
  • 6.2.4.By Country
• 6.3.North America: Country Analysis
  • 6.3.1.United States Blood Culture Tests Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Product
      • 6.3.1.2.2.By Application
      • 6.3.1.2.3.By Technique
  • 6.3.2.Mexico Blood Culture Tests Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Product
      • 6.3.2.2.2.By Application
      • 6.3.2.2.3.By Technique
  • 6.3.3.Canada Blood Culture Tests Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Product
      • 6.3.3.2.2.By Application
      • 6.3.3.2.3.By Technique

7.Europe Blood Culture Tests Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Product
  • 7.2.2.By Application
  • 7.2.3.By Technique
  • 7.2.4.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.France Blood Culture Tests Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Product
      • 7.3.1.2.2.By Application
      • 7.3.1.2.3.By Technique
  • 7.3.2.Germany Blood Culture Tests Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Product
      • 7.3.2.2.2.By Application
      • 7.3.2.2.3.By Technique
  • 7.3.3.United Kingdom Blood Culture Tests Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Product
      • 7.3.3.2.2.By Application
      • 7.3.3.2.3.By Technique
  • 7.3.4.Italy Blood Culture Tests Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Product
      • 7.3.4.2.2.By Application
      • 7.3.4.2.3.By Technique
  • 7.3.5.Spain Blood Culture Tests Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Product
      • 7.3.5.2.2.By Application
      • 7.3.5.2.3.By Technique

8.Asia-Pacific Blood Culture Tests Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Product
  • 8.2.2.By Application
  • 8.2.3.By Technique
  • 8.2.4.By Country
• 8.3.Asia-Pacific: Country Analysis
  • 8.3.1.China Blood Culture Tests Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Product
      • 8.3.1.2.2.By Application
      • 8.3.1.2.3.By Technique
  • 8.3.2.India Blood Culture Tests Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Product
      • 8.3.2.2.2.By Application
  • 8.3.3.South Korea Blood Culture Tests Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Product
      • 8.3.3.2.2.By Application
      • 8.3.3.2.3.By Technique
  • 8.3.4.Japan Blood Culture Tests Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Product
      • 8.3.4.2.2.By Application
      • 8.3.4.2.3.By Technique
  • 8.3.5.Australia Blood Culture Tests Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Product
      • 8.3.5.2.2.By Application
      • 8.3.5.2.3.By Technique

9.South America Blood Culture Tests Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Product
  • 9.2.2.By Application
  • 9.2.3.By Technique
  • 9.2.4.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Blood Culture Tests Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Product
      • 9.3.1.2.2.By Application
      • 9.3.1.2.3.By Technique
  • 9.3.2.Argentina Blood Culture Tests Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Product
      • 9.3.2.2.2.By Application
      • 9.3.2.2.3.By Technique
  • 9.3.3.Colombia Blood Culture Tests Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Product
      • 9.3.3.2.2.By Application
      • 9.3.3.2.3.By Technique

10.Middle East and Africa Blood Culture Tests Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Product
  • 10.2.2.By Application
  • 10.2.3.By Technique
  • 10.2.4.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Blood Culture Tests Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Product
      • 10.3.1.2.2.By Application
      • 10.3.1.2.3.By Technique
  • 10.3.2.Saudi Arabia Blood Culture Tests Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Product
      • 10.3.2.2.2.By Application
      • 10.3.2.2.3.By Technique
  • 10.3.3.UAE Blood Culture Tests Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Product
      • 10.3.3.2.2.By Application
      • 10.3.3.2.3.By Technique
  • 10.3.4.Egypt Blood Culture Tests Market Outlook
    • 10.3.4.1.Market Size Forecast
      • 10.3.4.1.1.By Value
    • 10.3.4.2.Market Share Forecast
      • 10.3.4.2.1.By Product
      • 10.3.4.2.2.By Application
      • 10.3.4.2.3.By Technique

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Merger Acquisition (If Any)
• 12.2.Product Launches (If Any)
• 12.3.Recent Developments

13.Porters Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Products

14.Competitive Landscape

• 14.1.Becton Dickinson Company
  • 14.1.1.Business Overview
  • 14.1.2.Company Snapshot
  • 14.1.3.Products Services
  • 14.1.4.Financials (As Reported)
  • 14.1.5.Recent Developments
  • 14.1.6.Key Personnel Details
  • 14.1.7.SWOT Analysis
• 14.2.Terumo Corporation
• 14.3.Bruker Corporation
• 14.4.bioMerieux
• 14.5.T2 Biosystems Inc.
• 14.6.Luminex Corporation
• 14.7.Abbott Laboratories Inc.
• 14.8.Siemens Healthineers AG
• 14.9.Danaher Corporation
• 14.10.F. Hoffmann-La Roche Ltd

15.Strategic Recommendations

16.About Us Disclaimer